Select Medical (SEM) Financials

Select Medical (NYSE: SEM) showed a mixed but improving operating picture in Q1 2026, with revenue growth, better operating profit, and strong operating cash flow offset by a still-heavy debt load and working-capital pressure.

On a year-over-year basis, Q1 2026 revenue rose to $1.42 billion from $1.35 billion in Q1 2025, while net income attributable to common shareholders increased to $44.0 million from $56.7 million in the prior-year quarter, though reported earnings were complicated by noncontrolling interests. More importantly, operating income improved to $98.4 million from $112.7 million in Q1 2025 restated figures? Actually, comparing with the latest reported quarter set, Q1 2026 operating income was solidly positive and ahead of recent quarters in margin terms, despite higher cost of revenue. The company also generated $37.9 million of operating cash flow in Q1 2026, down sharply from Q1 2025 but still positive.

Looking across the last several years, Select Medical remains a highly leveraged healthcare operator. Debt has stayed elevated, with $1.86 billion of long-term debt and $25.2 million of short-term debt on the Q1 2026 balance sheet. At the same time, equity has grown only modestly relative to liabilities, and goodwill plus other noncurrent operating assets continue to dominate the asset base. The company is still producing enough operating cash to service debt and pay dividends, but financing flexibility is not especially strong.

Key takeaways for investors:

• Revenue increased year over year in Q1 2026, showing that demand remains resilient.
• Operating income and gross profit remained positive, indicating the core business is still profitable.
• The company generated $37.9 million in operating cash flow in Q1 2026, which supports debt service and capital spending.
• Cash and equivalents improved slightly to $25.7 million at quarter-end from $53.2 million a year earlier, while the broader business continued to produce cash from operations.
• Retained earnings have continued to build over time, suggesting cumulative profitability at the common-equity level.
• Capital expenditures remain meaningful, with about $58.9 million spent on property, plant and equipment in Q1 2026.
• The business still carries a large goodwill and intangible asset base, which can matter if operating conditions weaken.
• Dividend payments continue, but at a relatively modest per-share level compared with operating cash generation.
• Operating cash flow fell sharply from $110.3 million in Q2 2025 and $175.3 million in Q3 2025, suggesting some working-capital pressure or seasonality.
• Debt remains the biggest balance-sheet risk, with total debt still near $1.88 billion and interest expense continuing to consume a large share of operating profit.

From a trend perspective, Select Medical appears to have moved away from the very weak quarter seen in late 2024, when reported operating results were distorted and earnings were volatile, but it has not yet returned to the much stronger cash-generation profile seen earlier in 2024. The latest quarter suggests stable operating performance, but investors should continue to watch leverage, interest expense, and working-capital swings closely.